Metabolic support compounds and nutrients that aid healthy weight management and metabolic function.
9 itemsA focused look at how long fasting may take to engage autophagy, summarizing animal data, human intermittent fasting trials, fasting-mimicking diets, and traditional fasts—highlighting what’s known and what remains uncertain.
Does time-restricted eating (TRE) trigger autophagy? A focused, evidence-based review of mechanisms, human trials, and how TRE compares with other fasting models.
A focused look at fasting‑mimicking diets and autophagy: what human trials and animal studies suggest, how nutrient‑sensing pathways are involved, and where evidence is still emerging.
Research-based look at when autophagy may start during fasting, what triggers it, and how time-restricted eating, alternate-day fasting, fasting-mimicking diets, and Ramadan relate to autophagy.
A bioactive compound found in several plants, used in traditional Chinese and Ayurvedic medicine, studied for blood sugar regulation and metabolic health.
Diabetes management aims to prevent symptoms and long-term complications by maintaining near-normal glycemia while addressing cardiovascular, renal, eye, nerve, and foot risks. Western medicine defines diabetes biologically and relies on standardized diagnostics and evidence-based care pathways, including lifestyle, medications, and ongoing monitoring. Eastern and traditional systems such as Traditional Chinese Medicine (TCM) and Ayurveda conceptualize diabetes through pattern diagnoses (e.g., yin deficiency with heat; Madhumeha) and emphasize constitutional balance, diet, herbs, acupuncture, yoga, and mind–body practices. An integrative approach can combine the strengths of each: the proven risk reduction from Western protocols with patient-centered lifestyle, stress management, and culturally congruent dietary and herbal therapies when safe and appropriately monitored. In Western care, diagnosis uses objective criteria: HbA1c ≥6.5%, fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), 2-hour OGTT glucose ≥200 mg/dL (11.1 mmol/L), or random glucose ≥200 mg/dL with classic symptoms. HbA1c guides longitudinal control and risk; targets are individualized (often <7% for most adults, tighter or looser based on comorbidities, hypoglycemia risk, and life expectancy). Management prioritizes medical nutrition therapy (Mediterranean/plant-forward patterns, carbohydrate quality/quantity, and energy deficits for weight loss), physical activity (≥150 minutes/week moderate intensity plus resistance training), sleep, and smoking cessation. Pharmacologic therapy is tailored to cardiorenal risk: metformin is common first-line unless contraindicated; GLP-1 receptor agonists and SGLT2 inhibitors provide cardiovascular and renal protection independent of metformin; dual GIP/GLP-1 agents and insulin are used when needed. Monitoring includes HbA1c every 3 months until stable, self-monitoring of blood glucose or continuous glucose monitoring (CGM), annual kidney (eGFR, albuminuria), eye, and
Diabetes and hypertension commonly occur together and amplify each other’s risks for heart attack, stroke, kidney disease, retinopathy, and heart failure. Roughly two-thirds of adults with type 2 d...
Heart disease and diabetes are tightly linked cardiometabolic conditions that frequently co-occur and amplify each other’s risks. Cardiovascular disease (CVD)—including coronary artery disease, str...
Obesity and obstructive sleep apnea (OSA) are tightly interlinked conditions that reinforce one another through anatomical, metabolic, and neurohormonal pathways. Excess adiposity—particularly cent...
